Brief research report: OM-85 reduces SARS-COV-2 viral RNA expression in nasopharyngeal cells from COVID-19 patients
OM-85 is a bacterial lysate from common respiratory tract pathogens, with an excellent safety profile, widely used to prevent recurrent respiratory tract infections. Several studies have been reporting the immunomodulating properties and antiviral roles of OM-85. The COVID-19 pandemic, originating i...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-10-01
|
| Series: | Frontiers in Virology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fviro.2023.1111619/full |
| _version_ | 1827782591088951296 |
|---|---|
| author | Gisele Cassão Krist Helen Antunes João Ismael Budelon Gonçalvez Leonardo Duarte Santos Bruno Lopes Abbadi Cristiano Valim Bizarro Pablo Machado Luiz Augusto Basso Christian Pasquali Renato T. Stein Ana Paula Duarte de Souza |
| author_facet | Gisele Cassão Krist Helen Antunes João Ismael Budelon Gonçalvez Leonardo Duarte Santos Bruno Lopes Abbadi Cristiano Valim Bizarro Pablo Machado Luiz Augusto Basso Christian Pasquali Renato T. Stein Ana Paula Duarte de Souza |
| author_sort | Gisele Cassão |
| collection | DOAJ |
| description | OM-85 is a bacterial lysate from common respiratory tract pathogens, with an excellent safety profile, widely used to prevent recurrent respiratory tract infections. Several studies have been reporting the immunomodulating properties and antiviral roles of OM-85. The COVID-19 pandemic, originating in 2019, has presented a significant global public health crisis. While effective vaccines have been developed, vaccination rates vary considerably, and numerous concerning viral variants continue to emerge. The challenge persists in creating early interventions to halt the progression of the disease to its severe stages. To examine the therapeutic effect of OM-85 after SARS-CoV-2 infection and compared to recombinant human (rhINF-β) we collected nasopharyngeal cells from COVID-19 patients. The cells were treated ex-vivo with OM-85 or hrINF-β and the response was analyzed after 24h for gene expression by real-time PCR. We found that OM-85 decreased the SARS-CoV-2 N1 gene expression and increased RIG-I (DDX58) in these cells. The expression of ACE2 was undetected in these samples. These data support the antiviral effect of OM-85 against SARS-CoV-2. |
| first_indexed | 2024-03-11T15:34:05Z |
| format | Article |
| id | doaj.art-65130d6acd124b37b7a0b73ab7087035 |
| institution | Directory Open Access Journal |
| issn | 2673-818X |
| language | English |
| last_indexed | 2024-03-11T15:34:05Z |
| publishDate | 2023-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Virology |
| spelling | doaj.art-65130d6acd124b37b7a0b73ab70870352023-10-27T00:18:04ZengFrontiers Media S.A.Frontiers in Virology2673-818X2023-10-01310.3389/fviro.2023.11116191111619Brief research report: OM-85 reduces SARS-COV-2 viral RNA expression in nasopharyngeal cells from COVID-19 patientsGisele Cassão0Krist Helen Antunes1João Ismael Budelon Gonçalvez2Leonardo Duarte Santos3Bruno Lopes Abbadi4Cristiano Valim Bizarro5Pablo Machado6Luiz Augusto Basso7Christian Pasquali8Renato T. Stein9Ana Paula Duarte de Souza10Laboratory of Clinical and Experimental Immunology, Health and Life Science School – Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS), Porto Alegre, BrazilLaboratory of Clinical and Experimental Immunology, Health and Life Science School – Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS), Porto Alegre, BrazilLaboratory of Clinical and Experimental Immunology, Health and Life Science School – Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS), Porto Alegre, BrazilLaboratory of Clinical and Experimental Immunology, Health and Life Science School – Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS), Porto Alegre, BrazilMolecular and Functional Biology Research Center (CPBMF), PUCRS, Porto Alegre, BrazilMolecular and Functional Biology Research Center (CPBMF), PUCRS, Porto Alegre, BrazilMolecular and Functional Biology Research Center (CPBMF), PUCRS, Porto Alegre, BrazilMolecular and Functional Biology Research Center (CPBMF), PUCRS, Porto Alegre, BrazilPreclincal Research Department, OM-Pharma, Geneva, SwitzerlandSchool of Medicine, PUCRS, Porto Alegre, BrazilLaboratory of Clinical and Experimental Immunology, Health and Life Science School – Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS), Porto Alegre, BrazilOM-85 is a bacterial lysate from common respiratory tract pathogens, with an excellent safety profile, widely used to prevent recurrent respiratory tract infections. Several studies have been reporting the immunomodulating properties and antiviral roles of OM-85. The COVID-19 pandemic, originating in 2019, has presented a significant global public health crisis. While effective vaccines have been developed, vaccination rates vary considerably, and numerous concerning viral variants continue to emerge. The challenge persists in creating early interventions to halt the progression of the disease to its severe stages. To examine the therapeutic effect of OM-85 after SARS-CoV-2 infection and compared to recombinant human (rhINF-β) we collected nasopharyngeal cells from COVID-19 patients. The cells were treated ex-vivo with OM-85 or hrINF-β and the response was analyzed after 24h for gene expression by real-time PCR. We found that OM-85 decreased the SARS-CoV-2 N1 gene expression and increased RIG-I (DDX58) in these cells. The expression of ACE2 was undetected in these samples. These data support the antiviral effect of OM-85 against SARS-CoV-2.https://www.frontiersin.org/articles/10.3389/fviro.2023.1111619/fullCOVID-19SARS-CoV-2OM-85nasopharyngealRIG-Iepithelial cells |
| spellingShingle | Gisele Cassão Krist Helen Antunes João Ismael Budelon Gonçalvez Leonardo Duarte Santos Bruno Lopes Abbadi Cristiano Valim Bizarro Pablo Machado Luiz Augusto Basso Christian Pasquali Renato T. Stein Ana Paula Duarte de Souza Brief research report: OM-85 reduces SARS-COV-2 viral RNA expression in nasopharyngeal cells from COVID-19 patients Frontiers in Virology COVID-19 SARS-CoV-2 OM-85 nasopharyngeal RIG-I epithelial cells |
| title | Brief research report: OM-85 reduces SARS-COV-2 viral RNA expression in nasopharyngeal cells from COVID-19 patients |
| title_full | Brief research report: OM-85 reduces SARS-COV-2 viral RNA expression in nasopharyngeal cells from COVID-19 patients |
| title_fullStr | Brief research report: OM-85 reduces SARS-COV-2 viral RNA expression in nasopharyngeal cells from COVID-19 patients |
| title_full_unstemmed | Brief research report: OM-85 reduces SARS-COV-2 viral RNA expression in nasopharyngeal cells from COVID-19 patients |
| title_short | Brief research report: OM-85 reduces SARS-COV-2 viral RNA expression in nasopharyngeal cells from COVID-19 patients |
| title_sort | brief research report om 85 reduces sars cov 2 viral rna expression in nasopharyngeal cells from covid 19 patients |
| topic | COVID-19 SARS-CoV-2 OM-85 nasopharyngeal RIG-I epithelial cells |
| url | https://www.frontiersin.org/articles/10.3389/fviro.2023.1111619/full |
| work_keys_str_mv | AT giselecassao briefresearchreportom85reducessarscov2viralrnaexpressioninnasopharyngealcellsfromcovid19patients AT kristhelenantunes briefresearchreportom85reducessarscov2viralrnaexpressioninnasopharyngealcellsfromcovid19patients AT joaoismaelbudelongoncalvez briefresearchreportom85reducessarscov2viralrnaexpressioninnasopharyngealcellsfromcovid19patients AT leonardoduartesantos briefresearchreportom85reducessarscov2viralrnaexpressioninnasopharyngealcellsfromcovid19patients AT brunolopesabbadi briefresearchreportom85reducessarscov2viralrnaexpressioninnasopharyngealcellsfromcovid19patients AT cristianovalimbizarro briefresearchreportom85reducessarscov2viralrnaexpressioninnasopharyngealcellsfromcovid19patients AT pablomachado briefresearchreportom85reducessarscov2viralrnaexpressioninnasopharyngealcellsfromcovid19patients AT luizaugustobasso briefresearchreportom85reducessarscov2viralrnaexpressioninnasopharyngealcellsfromcovid19patients AT christianpasquali briefresearchreportom85reducessarscov2viralrnaexpressioninnasopharyngealcellsfromcovid19patients AT renatotstein briefresearchreportom85reducessarscov2viralrnaexpressioninnasopharyngealcellsfromcovid19patients AT anapauladuartedesouza briefresearchreportom85reducessarscov2viralrnaexpressioninnasopharyngealcellsfromcovid19patients |